GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
GSK plcNYSE: GSK
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of £2.2B rose 2.9% year over year, ahead of the -13.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 3.9% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.
Context
- Selling, general & admin amounted to 27.8% of revenue in FY2025, down 7.3 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 16 analysts of £10.35B (+13.9%) for the fiscal year ending Dec 2026, a step up from the -17.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- £2.2B+3.9% QoQ
- Last fiscal yearDec 2025
- £9.09B-17.5% YoY
- LTMJun 2026
- £9.2B-13.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
GBP · from the income statement
- Latest · FY2025
- 9.09B GBP
- Year-over-year change
- -17.5%
- 4-year CAGR
- +6.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.09B | -17.5% |
| FY2024 | 2024-12-31 | 11.02B | +17.4% |
| FY2023 | 2023-12-31 | 9.39B | +12.1% |
| FY2022 | 2022-12-31 | 8.37B | +18.4% |
| FY2021 | 2021-12-31 | 7.07B | — |
Selling, General & Admin vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.8% is the lowest of 10, against a peer median of +1.8%.
- Selling, general & admin amounts to 27.7% of revenue for GSK, versus a peer median of 20.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 64.84B DKK | -9.7% | +11.5% | 19.7% | |
| LTM Sep 2026 | $25.5B USD | +11.0% | +5.4% | 25.7% | |
| LTM Sep 2026 | $20.52B USD | +0.5% | +4.5% | 33.0% | |
| LTM Jun 2026 | $13.72B USD | -1.7% | +0.3% | 21.5% | |
| LTM Jun 2026 | $13.13B USD | -0.1% | +3.0% | 23.6% | |
| LTM Jun 2026 | $12.24B USD | +25.6% | +22.3% | 15.4% | |
| LTM Jun 2026 | $10.39B USD | +10.8% | +3.5% | 15.7% | |
| LTM Jun 2026 | €9.82B EUR | +9.8% | +5.4% | 20.1% | |
| LTM Jun 2026 | £9.2B GBP | -13.8% | +2.8% | 27.7% | |
| LTM Jun 2026 | $7B USD | +1.8% | +9.2% | 18.4% | |
| Peer median (excluding GSK) | — | +1.8% | +5.4% | 20.1% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 24.7B | 29.32B | 30.33B | 31.38B | 32.67B |
| Cost of Revenue | 8.16B | 9.55B | 8.57B | 9.05B | 9.02B |
| Gross Profit | 16.53B | 19.77B | 21.76B | 22.33B | 23.65B |
| Gross Margin | 66.9% | 67.4% | 71.8% | 71.2% | 72.4% |
| Research & Development | 5.02B | 5.49B | 6.22B | 6.4B | 7.53B |
| Selling, General & Admin | 7.07B | 8.37B | 9.39B | 11.02B | 9.09B |
| Operating Expenses | 12.18B | 13.34B | 15.02B | 18.31B | 15.31B |
| Depreciation & Amortization | 2.12B | 2.15B | 2.29B | 2.55B | 2.31B |
| EBITDA | 6.49B | 8.6B | 9.08B | 6.67B | 10.4B |
| EBITDA Margin | 26.3% | 29.3% | 29.9% | 21.3% | 31.8% |
| Operating Income | 4.36B | 6.43B | 6.75B | 4.02B | 8.34B |
| Operating Margin | 17.6% | 21.9% | 22.2% | 12.8% | 25.5% |
| Interest Income | 28M | 64.27M | 40M | 67.39M | 56M |
| Interest Expense | 784M | 855.53M | 775M | 657.58M | 687M |
| Other Income / Expenses | (758M) | (805M) | (681M) | (544M) | (937M) |
| Income Before Tax | 3.6B | 5.63B | 6.06B | 3.48B | 7.4B |
| Pre-Tax Margin | 14.6% | 19.2% | 20.0% | 11.1% | 22.7% |
| Income Tax Expense | 83M | 707M | 756M | 526M | 1.11B |
| Net Income | 4.39B | 14.96B | 4.93B | 2.58B | 5.72B |
| Net Margin | 17.8% | 51.0% | 16.2% | 8.2% | 17.5% |
| EPS (Basic) | 2.74 | 7.44 | 2.44 | 1.26 | 2.82 |
| EPS (Diluted) | 2.70 | 7.32 | 2.40 | 1.24 | 2.78 |
| Weighted Avg Shares | 1.6B | 2.01B | 2.03B | 2.04B | 2.03B |
| Weighted Avg Shares (Diluted) | 1.62B | 2.04B | 2.06B | 2.07B | 2.06B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.